The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

Coulier, 66, was diagnosed with HPV-related oropharyngeal tongue cancer in October, he told TODAY.com in a phone interview.

EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma: Lund, Sweden Tuesday, November 18, 2025, 11:00 Hrs [IST] BioInvent In ...

New research challenges the status quo that cancer treatments are responsible for accelerating the aging process, indicating that cancer itself also plays a role. A team of researchers from Moffitt ...